五痹山药丸经调控骨髓T细胞归巢改善糖皮质激素性骨质疏松
该研究以地塞米松诱导的GIOP小鼠为对象,观察五痹山药丸的抗骨质疏松作用及免疫中介机制。结果显示五痹山药丸可改善骨强度与骨微结构,其作用可能与调控CXCL10-CXCR3轴、抑制骨髓Th17细胞活化及调节RANKL/RANK/OPG通路有关。
要点
- 五痹山药丸可改善GIOP小鼠骨强度与骨微结构。
- 其作用可能与抑制骨髓异常T细胞归巢及Th17活化相关。
- IL-17A或为连接免疫调节与骨代谢的关键桥接因子。
核心结论
- 五痹山药丸可能通过调控CXCL10-CXCR3轴抑制异常T细胞归巢至骨髓,减少Th17细胞活化与IL-17A分泌,从而恢复RANKL/RANK/OPG平衡,发挥抗GIOP作用。
研究设计与样本
- 研究为小鼠实验,采用地塞米松10 mg/kg每三天腹腔注射建立GIOP模型,并以五痹山药丸高1.5 g/kg、中0.75 g/kg、低0.375 g/kg灌胃20周。
- 采用HPLC分析五痹山药丸化学成分,并通过转录组学、流式细胞术及骨代谢指标检测探讨机制。
主要发现
- HPLC显示五痹山药丸中松果菊苷、毛蕊花糖苷、五味子醇浓度分别为7.82 mg/g、2.18 mg/g、0.32 mg/g。
- 五痹山药丸可提高GIOP小鼠体重、握力及肛温/背温等一般生理参数。
- 五痹山药丸可提高骨体积/组织体积、骨小梁厚度与数量,降低骨小梁分离度与结构模型指数。
- 转录组学提示五痹山药丸可能调控破骨细胞分化、IL-17A及NF-κB等通路。
- 五痹山药丸可增加脾脏T细胞、B细胞及CD4⁺ T细胞比例,下调CXCL10与CXCR3表达,抑制股骨CD4⁺ Th17细胞活化。
临床怎么用
- 本研究为动物实验,结果提示五痹山药丸抗GIOP可能涉及免疫中介机制,尚不能直接推导至临床用药决策。
局限性
- 原文摘要未明确报告研究局限性,故不列具体局限内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The disruption of bone immune function and bone metabolism homeostasis is intricately linked to the onset and progression of glucocorticoid-induced osteoporosis (GIOP). From the perspective of indirect pharmacology, bone immune cells act as critical intermediate mediators that bridge systemic drug exposure and local bone tissue responses. Wubi Shanyao Pills (WBSY), a Chinese patent medicine, have been shown to modulate T lymphocyte levels in naturally aging mice and improve bone strength. However, whether WBSY exerts anti-GIOP effects through an indirect immunomodulatory pattern and its underlying intermediate mechanisms remain unclear. PURPOSE: This study aims to elucidate the effects and mechanisms of WBSY on GIOP in mice. METHODS: Initially, the chemical constituents of WBSY were characterized using high-performance liquid chromatography (HPLC). Following this, a GIOP mouse model was developed through intraperitoneal administration of dexamethasone at a dosage of 10 mg/kg every three days. The mice were subsequently treated with WBSY at varying dosages-high (1.5 g/kg), medium (0.75 g/kg), and low (0.375 g/kg)-via gavage over a 20-week duration. Throughout the experimental period, general physiological parameters of the mice were systematically monitored. Bone mass alterations were subsequently assessed through bone strength measurements, micro-computed tomography analysis of bone tissue, and histopathological examination. Potential target pathways were identified via transcriptomic analysis. Furthermore, bone immunology-related parameters were evaluated using flow cytometry, including the proportion of T lymphocytes in the spleen and bone marrow, as well as the expression levels of the CXC chemokine ligand 10-chemokine receptor 3 (CXCL10-CXCR3) axis. Concurrently, key indicators of the bone metabolism pathway, such as the Receptor Activator of Nuclear Factor-κB (RANK), Receptor Activator of Nuclear Factor-κB ligand (RANKL), and osteoprotegerin (OPG), were further analyzed. RESULTS: The results of the HPLC analysis demonstrated that the concentrations of echinacoside, acteoside, and schisandrol in WBSY were 7.82 mg/g, 2.18 mg/g, and 0.32 mg/g, respectively. Subsequently, the findings revealed that WBSY significantly enhanced general physiological parameters, including body weight, grip strength, and anal/back temperature, in GIOP mice. WBSY not only enhanced bone strength and mitigated pathological damage to the femur, but also significantly improved bone microarchitecture. This improvement was evidenced by an increase in bone volume/tissue volume, trabecular thickness, and trabecular number, alongside a reduction in trabecular separation and the structural model index. Furthermore, transcriptomic analysis indicated that WBSY may exert anti-GIOP effects by modulating key pathways, including osteoclast differentiation, interleukin-17A (IL-17A), and nuclear factor kappa B (NF-κB). At the immunological level, WBSY was shown to increase the proportion of T cells, B cells, and CD4⁺ T cells in the spleen, downregulate the expression of CXCL10 and CXCR3, and inhibit the activation of CD4⁺ Th17 cells in the femur. At the molecular level, WBSY modulated the expression of key molecules involved in the bone metabolism pathway, including RANK, RANKL, and OPG. It consistently downregulated the levels of femoral inflammation signaling molecules such as tumor necrosis factor receptor-associated factor 6 (TRAF6), phosphorylated IκB kinase β/IκB kinase β (p-IKKβ/IKKβ), and phosphorylated nuclear factor kappa B/nuclear factor kappa B (p-NF-κB/NF-κB). Additionally, WBSY reduced the concentrations of bone resorption markers, including tartrate-resistant acid phosphatase (TRAP) and β-C-telopeptide of type I collagen (β-CTX). Concurrently, it upregulated the expression of osteogenic molecules such as Runt-related transcription factor 2 (Runx2) and bone morphogenetic protein 2 (BMP2), leading to increased concentrations of bone formation markers, including bone-specific alkaline phosphatase (BALP), procollagen type I N-terminal propeptide (PINP), and osteocalcin (BGP). CONCLUSIONS: In summary, this study suggests that WBSY exerts anti-GIOP effects via an indirect pharmacological mechanism. WBSY may modulate the CXCL10-CXCR3 axis to inhibit aberrant T cell homing to the bone marrow, thereby reducing the excessive activation of bone marrow-resident Th17 cells and the secretion of the key bridging cytokine IL-17A. This indirect immunomodulation may subsequently restore the balance of the RANKL/RANK/OPG pathway, ultimately synergistically promoting bone formation and inhibiting bone resorption.
引用
- Dong YJ, Zhu JY, Su J, et al. Wubi Shanyao Pills ameliorate glucocorticoid-induced osteoporosis by regulating bone marrow T cell homing as an immune intermediate to restore bone metabolism. Chin Med. 2026. PMID: 42393739. doi:10.1186/s13020-026-01452-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。